DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20200357

Comparative study of intravenous hydralazine and labetalol in severe hypertensive disorders of pregnancy

Anupma Kumari, Renu Rohatgi, Amrita Singh, Raj Kumar

Abstract


Background: Hypertensive disorders of pregnancy are among the most common medical complications of pregnancy and major cause of maternal, fetal and neonatal morbidity and mortality. The purpose of this study was to compare the efficacy and safety of intravenous hydralazine and labetalol for management of severe hypertensive disorders of pregnancy.

Methods: This prospective study was conducted among 100 women admitted with SBP ≥ 160 or DBP ≥ 110 mmHg or both. Patients were divided into 2 groups randomly: labetalol and hydralazine group.

Results: Majority of patients (38%) were in the age group of 21-25 years and primigravida (52%). There was more significant decrease in the systolic, diastolic and mean arterial blood pressure at the end of 15 and 30 minutes in labetalol group. Labetalol required fewer doses as compared to hydralazine to achieve the target blood pressure (average 1.95 versus 3.1). Total numbers of term deliveries were 19 (38%) in hydralazine group and 16 (32%) in labetalol group. Pre-term deliveries in hydralazine and labetalol group were 14 (28%) and 15 (30%) respectively. Headache was significantly more common in hydralazine treated patients than labetalol group.

Conclusions: Both hydralazine and labetalol were effective and well-tolerated in the treatment of severe hypertensive disorders of pregnancy. Labetalol may be preferred because it was more effective in lowering the systolic blood pressure, diastolic blood pressure and mean arterial pressure to achieve target levels with less number of doses.


Keywords


Hydralazine, Hypertensive disorders of pregnancy, Labetalol, Mean arterial blood pressures

Full Text:

PDF

References


Moodley J. Maternal deaths associated with hypertension in South Africa: lessons to learn from the saving mothers report, 2005-2007. Cardiovasc J Afr. 2011;22(1):31-5.

Shruti S, Dubhashi R, Wani J, Priti Chikhal, Hegde CV. PIH confounding situations, management dilemmas and severe consequences: does antenatal care have a role? Bombay Hospital J. 2008;50:34-7.

Roberts RP, Sibai BM. Diagnosis and management of hypertensive emergencies complicating pregnancy. Current Women`s Health Reviews. 2016;12:39-47.

Granger JP, Alexander BT, Bennett WA, Khalil RA. Pathophysiology of pregnancy-induced hypertension. Am J Hypertens. 2001a;14(6):178S-85S.

Granger JP, Alexander BT, Llinas MT, Bennett WA, Khalil RA. Pathophysiology of hypertension during preeclampsia linking placental ischemia with endothelial dysfunction. Hyper. 2001b;38(3):718-22.

Chandiramani M, Joash K, Shennan AH. Options and decision making: hypertensive disorders of pregnancy. Future Cardiol. 2010;6(4):535-46.

The American College of Obstetricians and Gynecologists. Emergent therapy for acute-onset, severe hypertension with preeclampsia or eclampsia. Committee Opinion. 2011;514:1-4.

National Institute of Health and Clinical Excellence. Hypertension in Pregnancy, The management of hypertensive disorders during pregnancy. Clinical guidelines CG107, 2010. Available at: http://guidance.nice.org.uk/CG107. Accessed June 2019.

Duley L, Henderson-Smart DJ, Meher S. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database of Systematic Reviews. 2006;3:Art. No.:CD001449.

Witlin AG, Sibai BM. Magnesium sulfate therapy in preeclampsia and eclampsia. Obstet Gynecol. 1998;92:883-9.

Magee LA, Cham C, Waterman EJ, Ohlsson A, von Dadelszen P. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ. 2003;327:955-60.

Vigil-De Gracia P, Lasso M, Ruiz E, Vega-Malek JC, de Mena FT, López JC. Severe hypertension in pregnancy: hydralazine or labetalol. A randomized clinical trial. Eur J Obstet Gynecol Reprod Biol. 2006;128(1-2):157-62.

Pritchard JA, Cunningham FG, Pritchard SA. The Parkland Memorial Hospital protocol for the treatment of eclampsia: evaluation of 245 cases. Am J Obstet Gynaecol. 1984;148:951-63.

Bell MJ. A historical overview of preeclampsia-eclampsia. J Obstet Gynecol Neonatal Nurs. 2010;39(5):510-8.

Nombur LI, Agida ET, Isah AY, Ekele BA. A comparison of hydralazine and labetalol in the management of severe preeclampsia. J Women’s Health Care. 2014;3:6.

Prakash J, Pandey LK, Singh AK, Kar B. Hypertension in pregnancy: hospital-based study. J Assoc Physicians India. 2006;54:273-8.

Silva LM, Coolman M, Steegers EA, Jaddoe VW, Moll HA, Hofman A. Low socioeconomic status is a risk factor for preeclampsia: the generation R study. J Hypertens. 2008;26(6):1200-8.

Khan A, Hafeez S, Nasrullah FD. Comparison of hydralazine and labetalol to lower severe hypertension in pregnancy. Pak J Med Sci. 2017;33(2):466-70.

Rahim R, Nahar K, Khan IA. Platelet count in 100 cases of pregnancy induced hypertension. Mymensingh Med J. 2010;19(1):5-9.

Bakhda RN. Clinical study of fundus findings in pregnancy induced hypertension. J Family Med Prim Care. 2016;5(2):424-9.

Patel T, Dudhat A. Relationship of serum uric acid level to maternal and perinatal outcome in patients with hypertensive disorders of pregnancy. Gujrat Med J. 2014;69(2):45-7.

Bilano VL, Ota E, Ganchimeg T, Mori R, Souza JP. Risk factors of pre-eclampsia/eclampsia and its adverse outcomes in low- and middle-income countries: a WHO secondary analysis. PLoS One. 2014;9(3):e91198.

Mable WC, Gonzalez AR, Sibai BM, Amon E. A comparative trial of labetalol and hydralazine in the acute management of severe hypertension complicating pregnancy. Obstet Gynecol. 1987;70:328-33.

Trivedi S, Vyas L, Ratnu L, Gupta P, Agarwal P, Patel T. A comparative study of IV Labetalol and IV Hydralazine on mean arterial blood pressure changes in pregnant women with hypertensive emergency. Sch J App Med Sci. 2016;4(6F):2256-9.

Deka N, Das GC, Baishya S, Yadav S. A comparative study of hydralazine versus labetalol in the management of pregnancy induced hypertension (PIH). Sch J App Med Sci. 2016;4(11B):3996-9.